These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 8141833

  • 1. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia.
    Myant NB.
    Atherosclerosis; 1993 Dec; 104(1-2):1-18. PubMed ID: 8141833
    [Abstract] [Full Text] [Related]

  • 2. Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia.
    Pimstone SN, Defesche JC, Clee SM, Bakker HD, Hayden MR, Kastelein JJ.
    Arterioscler Thromb Vasc Biol; 1997 May; 17(5):826-33. PubMed ID: 9157944
    [Abstract] [Full Text] [Related]

  • 3. Familial defective apolipoprotein B100: clinical characteristics of 54 cases.
    Rauh G, Keller C, Kormann B, Spengel F, Schuster H, Wolfram G, Zöllner N.
    Atherosclerosis; 1992 Feb; 92(2-3):233-41. PubMed ID: 1632851
    [Abstract] [Full Text] [Related]

  • 4. Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects.
    Raal FJ, Pilcher G, Rubinsztein DC, Lingenhel A, Utermann G.
    Atherosclerosis; 1997 Feb 28; 129(1):97-102. PubMed ID: 9069523
    [Abstract] [Full Text] [Related]

  • 5. Familial defective apolipoprotein B-100.
    Hansen PS.
    Dan Med Bull; 1998 Sep 28; 45(4):370-82. PubMed ID: 9777289
    [Abstract] [Full Text] [Related]

  • 6. Does the presence of the 3500 mutant apolipoprotein B-100 in low density lipoprotein particles affect their atherogenicity?
    Maher VM, Gallagher JJ, Thompson GR, Myant NB.
    Atherosclerosis; 1995 Nov 28; 118(1):105-10. PubMed ID: 8579620
    [Abstract] [Full Text] [Related]

  • 7. Phenotypic heterogeneity associated with defective apolipoprotein B-100 and occurrence of the familial hypercholesterolemia phenotype in the absence of an LDL-receptor defect within a Canadian kindred.
    Davignon J, Dufour R, Roy M, Bétard C, Ma Y, Ouellette S, Boulet L, Lussier-Cacan S.
    Eur J Epidemiol; 1992 May 28; 8 Suppl 1():10-7. PubMed ID: 1505645
    [Abstract] [Full Text] [Related]

  • 8. Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function.
    Myant NB, Gallagher JJ, Knight BL, McCarthy SN, Frostegård J, Nilsson J, Hamsten A, Talmud P, Humphries SE.
    Arterioscler Thromb; 1991 May 28; 11(3):691-703. PubMed ID: 1674216
    [Abstract] [Full Text] [Related]

  • 9. Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100.
    Rubinsztein DC, Raal FJ, Seftel HC, Pilcher G, Coetzee GA, van der Westhuyzen DR.
    Arterioscler Thromb; 1993 Jul 28; 13(7):1076-81. PubMed ID: 8318509
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Familial defective apolipoprotein B-100 (R3500Q) in Northern Ireland.
    McClean E, Graham CA, Ward AJ, Young IS, Martin S, Nicholls DP.
    Br J Biomed Sci; 1999 Jul 28; 56(4):258-62. PubMed ID: 10795369
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Familial defective apolipoprotein B-100: a lesson from homozygous and heterozygous patients.
    Ceska R, Vrablík M, Horínek A.
    Physiol Res; 2000 Jul 28; 49 Suppl 1():S125-30. PubMed ID: 10984082
    [Abstract] [Full Text] [Related]

  • 14. Hypocholesterolemic effects of cholestyramine and colestipol in patients with familial defective apolipoprotein B-100.
    Schmidt EB, Illingworth DR, Bacon S, Mahley RW, Weisgraber KH.
    Atherosclerosis; 1993 Jan 25; 98(2):213-7. PubMed ID: 8457260
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Familial defective apolipoprotein B versus familial hypercholesterolemia: an assessment of risk.
    Fouchier SW, Defesche JC, Kastelein JJ, Sijbrands EJ.
    Semin Vasc Med; 2004 Aug 25; 4(3):259-64. PubMed ID: 15630635
    [Abstract] [Full Text] [Related]

  • 17. Identification of defective binding of low density lipoprotein by the U937 proliferation assay in German patients with familial defective apolipoprotein B-100.
    Schewe CK, Schuster H, Hailer S, Wolfram G, Keller C, Zöllner N.
    Eur J Clin Invest; 1994 Jan 25; 24(1):36-41. PubMed ID: 8187806
    [Abstract] [Full Text] [Related]

  • 18. Familial defective apolipoprotein B-100: a common cause of primary hypercholesterolemia.
    Rauh G, Keller C, Schuster H, Wolfram G, Zöllner N.
    Clin Investig; 1992 Jan 25; 70(1):77-84. PubMed ID: 1600334
    [Abstract] [Full Text] [Related]

  • 19. Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia.
    Miserez AR, Keller U.
    Arterioscler Thromb Vasc Biol; 1995 Oct 25; 15(10):1719-29. PubMed ID: 7583549
    [Abstract] [Full Text] [Related]

  • 20. Decreased binding of apolipoprotein (a) to familial defective apolipoprotein B-100 (Arg3500-->Gln). A study of the assembly of recombinant apolipoprotein (a) with mutant low density lipoproteins.
    Durovic S, März W, Frank S, Scharnagl H, Baumstark MW, Zechner R, Kostner GM.
    J Biol Chem; 1994 Dec 02; 269(48):30320-5. PubMed ID: 7982944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.